Akèy › Limfòm Non-Hodgkin › Oregon
Etid klinik pou Limfòm Non-Hodgkin nan Oregon
14 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Providence Health & Services, Portland
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Oregon Health & Science University (OHSU), Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Oncology Associates of Oregon, P.C, Eugene
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Oregon Health and Science University Knight Cancer Institute, Portland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Providence Neurological Specialties West, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Local Institution - 0016, Portland
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jan 22, 2026 · NCT06357754SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.